AbbVie (ABBV) and Roche (RHHBY.OB) have halted five studies of their ABT-199 drug for leukemia and lymphoma after two patients died of tumor lysis syndrome, when the rapid destruction of malignant cells causes acute kidney failure. The firms are working to refine the dose to overcome the problem and hopes to start Phase III testing of ABT-199 this year, as planned.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Tue, 6:28PM)
at Benzinga.com (Mon, 11:05AM)
at Benzinga.com (Feb 20, 2015)
at Investor's Business Daily (Jan 30, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs